A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AHB-137 with Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients
Sponsor: AusperBio Therapeutics Inc.
A PHASE1 clinical study on Chronic Hepatitis B, this trial is completed. The trial is conducted by AusperBio Therapeutics Inc. and has accumulated 10 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Apr 2023 — Nov 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Feb 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AusperBio Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .